Inosine pranobex

PreclinicalSmall molecule

NNewport Pharmaceuticals International

Inosine pranobex is one of 30 small molecule programs targeting AIDS. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AIDSCompleted

Double-BlindCompleted

LymphadenopathyCompleted

Lymph Node DiseaseCompleted

AIDSPreclinical

Completed

Double-BlindPreclinical

Completed

LymphadenopathyPreclinical

Completed

Lymph Node DiseasePreclinical

Completed

Competition

Competitive Landscape

25 competitors in AIDS

#DrugCompanyPhaseTrials

Aralen

Tivicay

Vemlidy

Emtriva

Tybost

Norvir

Thalomid

Viramune

Trisenox

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Inosine pranobex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inosine pranobex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inosine pranobex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newport Pharmaceuticals International company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNewport Pharmaceuticals International

Inosine pranobex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymph Node Disease2 trials

Double-blind2 trials

Lymphadenopathy1 trial

Trial1 trial

AIDS1 trial

References

Drug Info

Quick Facts

Related News